

Sun Pharma announces launch of LEQSELVI™ (deuruxolitinib) in US for treating severe alopecia areata

14 July 2025 | News

LEQSELVI now available for prescription in US nationwide, offering a new option for eligible patients



Mumbai-based Sun Pharmaceutical Industries has announced that LEQSELVI™ (deuruxolitinib) 8 mg tablets is now available to healthcare providers and people living with severe alopecia areata in the US. Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body.

LEQSELVI is indicated for the treatment of adults with severe alopecia areata. With limited treatment options available to people living with severe alopecia areata in the US, the need for innovative therapies such as LEQSELVI remains critically important. LEQSELVI demonstrated rapid results in clinical trials with one third of patients regaining almost all of their hair by Week 24. Some patients (3%) achieved 80% or more scalp coverage as fast as 8 weeks.

The psychosocial impact of alopecia areata can be significant. Many people living with severe alopecia areata face psychological distress, including loss of self-confidence, due to the unpredictable nature of hair loss, underscoring the importance of effective treatment solutions. A medication that works fast is critical for alopecia areata patients. In a recent survey, 83% of patients preferred a treatment with attributes that included speed. Fast regrowth brings back more than just hair.

LEQSELVI may cause serious side effects including serious infections, malignancies, thrombosis, gastrointestinal perforations, and certain laboratory abnormalities. LEQSELVI (deuruxolitinib) 8 mg tablets is an oral selective inhibitor of Janus kinases JAK1 and JAK2 approved for the treatment of adults with severe alopecia areata.